These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31838956)

  • 1. Effect of iron chelation therapy on EPO-STAT5 signalling pathway and EPO resistance in iron-overloaded low-risk myelodysplastic syndrome patients.
    Zhang Y
    Hematology; 2020 Dec; 25(1):1-10. PubMed ID: 31838956
    [No Abstract]   [Full Text] [Related]  

  • 2. [Iron chelation therapy and its influence on the alleviation of EPO resistance in MDS patients].
    Zhang Y; Xiao C; Gu SC; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1027-32. PubMed ID: 25130822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To chelate or not to chelate in MDS: That is the question!
    Zeidan AM; Griffiths EA
    Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
    Zeidan AM; Pullarkat VA; Komrokji RS
    Crit Rev Oncol Hematol; 2017 Sep; 117():57-66. PubMed ID: 28807236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron chelation therapy in myelodysplastic syndromes: where do we stand?
    Mitchell M; Gore SD; Zeidan AM
    Expert Rev Hematol; 2013 Aug; 6(4):397-410. PubMed ID: 23991926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
    Wong CAC; Wong SAY; Leitch HA
    Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome.
    Hoefsloot LH; van Amelsvoort MP; Broeders LC; van der Plas DC; van Lom K; Hoogerbrugge H; Touw IP; Löwenberg B
    Blood; 1997 Mar; 89(5):1690-700. PubMed ID: 9057652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Tsang E; Leitch HA
    Ann Hematol; 2016 Jan; 95(1):73-78. PubMed ID: 26453076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of Abnormal Iron Metabolism on EPO-STAT5 Signaling Pathway in Anemia Patients].
    Zhang Y; Han S; Guo C; Zhang QX; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1726-1730. PubMed ID: 30501711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [STAT5 phosphorylation in CD34(+)CD38(-)CD123(+) bone marrow cells of the patients with myelodysplastic syndrome].
    Liu BN; Fu R; Wang HQ; Li LJ; Yue LZ; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Xing LM; Guan J; Wang J; Shao ZH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):480-3. PubMed ID: 22967386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron overload and chelation therapy in myelodysplastic syndromes.
    Temraz S; Santini V; Musallam K; Taher A
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.
    Ko BS; Chang CS; Chang MC; Chen TY; Chiou TJ; Chiu CF; Huang WL; Kao WY; Lan YJ; Lin SF; Tan TD; Tang JL; Tzeng CH; Wang PN; Yet SP; Tien HF
    Int J Hematol; 2014 Jul; 100(1):7-15. PubMed ID: 24924953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
    Steensma DP; Gattermann N
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):431-44. PubMed ID: 24507819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of hematopathology and alteration of JAK1/STAT3/STAT5 signaling axis in experimental myelodysplastic syndrome.
    Daw S; Chatterjee R; Law A; Law S
    Chem Biol Interact; 2016 Dec; 260():176-185. PubMed ID: 27725143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
    Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
    Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
    Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
    Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Leitch HA; Vickars LM
    Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndrome.
    Gu S; Zhao Y; Guo J; Xu F; Fei C; Zhang X; Xiao C; Chang C; Li X
    Tumour Biol; 2014 Mar; 35(3):2211-8. PubMed ID: 24142530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of Yisui Jiedu Recipe on JAK2-STAT5 signal transduction pathway in bone marrow hematopoietic cells from patients with myelodysplastic syndrome-refractory anemia].
    Tian SL; Zhou YM; Huang T; Xue ZZ; He W
    Zhong Xi Yi Jie He Xue Bao; 2008 Feb; 6(2):185-9. PubMed ID: 18241656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.